One in Four Bags of Cocaine Now Carries Fentanyl. There's Still No Medicine for What's Underneath It.

Nobody buying a gram of cocaine on a Friday night is asking for a synthetic opioid strong enough to stop the breathing of someone who has never touched an opioid in their life. According to the DEA’s 2025 National Drug Threat Assessment, that’s what a rising share of them are getting anyway. The finding comes from NFLIS, the National Forensic Laboratory Information System — the federal database that tracks what state and local crime labs actually find when they test drugs pulled from arrests and overdose scenes, as opposed to what a dealer claims is in the bag. Right now, one in four cocaine samples submitted to NFLIS also contains fentanyl.

This is not cocaine getting more dangerous in the way cocaine has always been dangerous — it is people with no opioid tolerance at all being handed opioid doses sized for bodies that use opioids daily, and a meaningful number of them are dying because nobody told them.

That single fact would be a major public health story on its own. It’s arriving, instead, as a subplot inside a bigger one — because everyone in this country has spent a decade being told, correctly, that fentanyl is the crisis. What almost nobody has been told is that stimulants are now riding along inside it, that stimulant deaths have exploded on their own separate curve for 24 straight years, and that in 2026, there is still not one FDA-approved medication for cocaine use disorder or methamphetamine use disorder. Not one. This isn’t because the biology is unsolvable. It’s because the money and the attention went somewhere else, and they’re still going somewhere else.

The Fourth Wave Was Never Really Hiding, We Just Weren’t Looking

Addiction researchers describe the overdose crisis in waves: prescription opioids first, then heroin, then illicit fentanyl. A peer-reviewed mortality study published this year in Substance Use & Misuse — “Methamphetamine and Cocaine Overdose Deaths in the United States, 1999–2023” — makes the case that we’re already deep into a fourth one, and it’s stimulants. The “fourth wave” isn’t a slogan; it names the specific, documented shift toward deaths where a stimulant and a synthetic opioid show up in the same toxicology report, at the same time, in the same body.

The numbers back it up starkly. Cocaine-involved deaths rose from 3,822 in 1999 to 29,449 in 2023. Methamphetamine-involved deaths rose from 547 to 34,855 over the same stretch — a 64-fold increase. Add them together and you get 64,304 deaths in a single year from two drugs that, as recently as the Clinton administration, killed a combined 4,369 people annually. The same researchers found something else worth sitting with: in 1999, fentanyl showed up in only about 8% of stimulant overdoses. By 2023, it was in 57%. Stimulants didn’t get less safe because cocaine and meth changed. They got less safe because the fentanyl supply grew up around them.

History Rhymes, and It Rhymes on Purpose

This isn’t the first time cocaine forced a national reckoning, and the last one is the reason this one has no medicine waiting for it. In the 1980s and ’90s, crack cocaine tore through Black urban communities while the country’s political response was mandatory minimums, not methadone clinics. The Anti-Drug Abuse Act of 1986 set a 100-to-1 sentencing disparity: five grams of crack triggered the same five-year federal mandatory minimum as 500 grams of powder cocaine — same drug, different form, wildly different sentence, and a defendant population split cleanly along race and class lines. That ratio stood for 24 years. The Fair Sentencing Act of 2010 cut it to 18-to-1 — not to parity, just to less indefensible. The country had a generation-defining cocaine crisis and answered it with prison capacity instead of pharmacology. We are still living inside that choice: the research infrastructure that might have produced a cocaine-use-disorder medication by now was never built, because the people using it were being sentenced, not studied.

The Only Thing That Works Is the One Thing Insurance Barely Pays For

Here is the part that should make you angry rather than resigned: an effective treatment for stimulant use disorder exists. It’s just not a pill. It’s called contingency management, and the concept is almost embarrassingly simple — patients give a urine sample on a regular schedule, and a negative test earns an immediate, tangible reward: cash, a gift card, points toward something they want. According to APA Monitor’s 2026 reporting, at least seven systematic reviews and meta-analyses now back it as the most effective intervention available for stimulant use disorder — more effective than cognitive behavioral therapy alone, and effective as a standalone treatment when nothing else is on offer. VA data cited in that reporting found contingency management cut all-cause mortality in stimulant use disorder patients by roughly 40% over a year, a protective effect in the range of what buprenorphine does for opioid use disorder. SAMHSA raised its incentive cap from $75 to $750 per patient per year in 2025, and a growing list of state Medicaid programs now reimburse for it. That is genuine, recent progress, and it’s real.

SAMHSA raised its incentive cap from $75 to $750 per patient per year in 2025, and a growing list of state Medicaid programs now reimburse for it.

It is also, by design, a patch over an empty shelf. Contingency management works because it rewards a behavior; it does nothing to touch the underlying neurochemistry the way naloxone reverses an opioid overdose or buprenorphine quiets an opioid craving. There is no equivalent for stimulants — no medication that blunts craving, no antagonist, nothing FDA-approved, full stop. Decades of trials on antidepressants, antipsychotics, and stimulant-replacement approaches have failed to produce one. That gap shows up hardest in emergency rooms, where methamphetamine-induced psychosis has driven a 245% rise in ED visits since 2003, according to a protocol evaluation published in PMC — and the same researchers note there are still no formal clinical guidelines for treating it. Picture what that means on the ground: a person in the grip of meth psychosis, convinced people outside the window are coming for them, brought into an ER where the physician on duty is improvising between a benzodiazepine and an antipsychotic because no consensus protocol tells them which, how much, or when — sometimes over-sedating, sometimes under-treating, every single time without a map.

What a Fourth Wave Actually Demands

None of this required a new discovery to prevent. It required treating cocaine and methamphetamine like the medical problem they’ve always been instead of the moral one they got filed under in 1986, and it required funding stimulant pharmacology the way fentanyl got funded once fentanyl started killing enough people to make headlines. Contingency management getting real money and real Medicaid coverage right now proves the system can move when it decides to — it just decided to move nearly forty years late, and only halfway. A person buying cocaine tonight still has no way to know if fentanyl is in it, and if they survive that, the country still hasn’t built them a medication for what made them buy it in the first place. That’s not a scientific mystery. It’s a bill nobody’s paid.